<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer immunotherapy targets &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cancer-immunotherapy-targets/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 26 Dec 2025 15:24:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Cancer immunotherapy targets &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>FASN Drives Immunosuppression in DLBCL Tumors</title>
		<link>https://bioengineer.org/fasn-drives-immunosuppression-in-dlbcl-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 26 Dec 2025 15:23:57 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy targets]]></category>
		<category><![CDATA[DLBCL tumor microenvironment]]></category>
		<category><![CDATA[FASN in DLBCL]]></category>
		<category><![CDATA[fatty acid metabolism in cancer]]></category>
		<category><![CDATA[immunosuppressive tumor microenvironment]]></category>
		<category><![CDATA[Lipid metabolism immune evasion]]></category>
		<category><![CDATA[Makalenin içeriğine ve odak noktalarına göre en uygun 5 etiket: **FASN immunosuppression]]></category>
		<category><![CDATA[metabolic immune regulation in lymphoma]]></category>
		<category><![CDATA[Metabolic immunotherapy** **Açıklama:** 1. **FASN immunosuppression:** Makalenin ana bulgusu ve başlığındaki temel konu. FASN'in immünsupresif etk]]></category>
		<category><![CDATA[Metabolic Reprogramming]]></category>
		<guid isPermaLink="false">https://bioengineer.org/fasn-drives-immunosuppression-in-dlbcl-tumors/</guid>

					<description><![CDATA[The intricate relationship between cellular metabolism and immune regulation has long been a focal point in cancer research, especially within the realm of hematologic malignancies. In a groundbreaking study published in Medical Oncology, researchers Cheng, Wang, Zhang, and colleagues illuminate the critical role of fatty acid synthase (FASN) in creating an immunosuppressive microenvironment in diffuse [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">311484</post-id>	</item>
		<item>
		<title>Erythropoietin Receptor Drives cDC1 Immune Tolerance</title>
		<link>https://bioengineer.org/erythropoietin-receptor-drives-cdc1-immune-tolerance/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 15:41:28 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Autoimmune disease mechanisms]]></category>
		<category><![CDATA[Cancer immunotherapy targets]]></category>
		<category><![CDATA[cDC1 immune regulation]]></category>
		<category><![CDATA[Erythropoietin receptor immune tolerance]]></category>
		<category><![CDATA[FOXP3-positive regulatory T cells]]></category>
		<guid isPermaLink="false">https://bioengineer.org/erythropoietin-receptor-drives-cdc1-immune-tolerance/</guid>

					<description><![CDATA[In a groundbreaking study published in Nature in 2025, researchers have unveiled a pivotal mechanism by which type 1 conventional dendritic cells (cDC1s) regulate immune tolerance, mediated by the erythropoietin receptor (EPOR). This discovery sheds new light on the sophisticated ways the immune system balances defenses against pathogens and tumors with the prevention of autoimmune [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">306022</post-id>	</item>
		<item>
		<title>TLR9 Levels Predict Outcomes in Lymphoma</title>
		<link>https://bioengineer.org/tlr9-levels-predict-outcomes-in-lymphoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 28 May 2025 13:57:25 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy targets]]></category>
		<category><![CDATA[diffuse large B-cell lymphoma]]></category>
		<category><![CDATA[Lymphoma subtypes]]></category>
		<category><![CDATA[Prognostic biomarkers]]></category>
		<category><![CDATA[TLR9 expression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tlr9-levels-predict-outcomes-in-lymphoma/</guid>

					<description><![CDATA[Recent advances in lymphoma research have spotlighted the pivotal role of immune receptors in the prognosis and treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common and aggressive forms of non-Hodgkin lymphoma. A groundbreaking study published in BMC Cancer elucidates how the expression of Toll-like receptor 9 (TLR9) intimately correlates with the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">247037</post-id>	</item>
	</channel>
</rss>
